Youngy Health(SZ:300247)2025-01-22 08:04Financial Projections - The estimated net profit attributable to shareholders for 2024 is projected to be between 42 million and 48 million yuan, representing a year-on-year increase of 58.00% to 80.57% compared to 26.58 million yuan in the previous year[4]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 34 million and 40 million yuan, indicating a year-on-year growth of 34.99% to 58.81% from 25.19 million yuan in the previous year[4]. Market Expansion - The company is actively expanding into overseas markets, contributing to an increase in operating income compared to the previous year[6]. Financial Reporting - The fair value of investment properties has decreased, leading to a discrepancy between the growth rates of net profit attributable to shareholders and net profit after deducting non-recurring gains and losses[6]. - The financial data presented is preliminary and has not been audited by the accounting firm, but there are no significant discrepancies in financial data discussions with the accounting firm[5].